Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

750.22 -4.65 (-0.62%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
42 43 Next >
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Is Regeneron Stock a Buy After a Regulatory Blow?
Don't write this company's eulogy too fast. 
Via The Motley Fool
Check Out What Whales Are Doing With REGN
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Why Regeneron Pharmaceuticals Stock Dipped This Week
A key regulatory setback is weighing on the biotech's stock. 
Via The Motley Fool
Check Out What Whales Are Doing With REGN
Via Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at... 
Via Benzinga
Is Regeneron's Stock in Trouble After This FDA Rejection?
The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue. 
Via The Motley Fool
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
Exposures COVID-19 Economy
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Catalent Stock Flopped Today
The company takes the fall for a failed drug application. 
Via The Motley Fool
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Regeneron Stock Is Trading Lower Today
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023
Via Benzinga
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%... 
Via Benzinga
Why Regeneron Stock Is Falling Today
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of... 
Via Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS